MAY - 8 2006

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

=	admitted Act of 4005, no corecce	U.S. I	Patent and Trad	emark Office; U.	S. DEPARTMENT OF COMMERCE displays a valid OMB control number.	
TRANSMITTAL FORM  (to be used for all correspondence after initial filling)		Application Number		10/603,214		
		Filing Date	June 25, 2			
		First Named Inventor	Frank BAF			
		Art Unit	3728			
		Examiner Name	JOHNSON	JOHNSON, Jerrold D. Of Correction		
		Altorney Docket Number	USAV2001/0077 US NP			
Total Number of Pages in This Submission 4						
ENCLOSURES (Check all that apply)						
Fee Transmittal Fo		Orawing(s)	\ <u>[</u>	Appeal	After Allowance Communication to TC  Appeal Communication to Board	
Fee Attached		Licensing-related Papers		of Appeals and Interforences		
Extension of Time Express Abandoni Information Disclo Certifled Copy of I Document(s) Reply to Missing F Incomplete Applic	declaration(s) Request ment Request sure Statement Priority Parts/ ation Rissing Parts CFR 1.52 or 1.53	<u> </u>	Address	(Appeal Proprie Status Other 8 below): Reque (2 pgs Form	Enclosure(s) (please identify	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name sanof	sanofi-aventis U.S. LLC					
Signature / / / / /						
Printed name Paul R DARKES / Ruel Albertle						
Date May 08, 2006 Reg. No. 33,862						
CERTIFICATE OF TRANSMISSION/MAILING  I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571,273.8300						
the date shown below: (USPTO FAX NO. 571,273.8300; Total No. of Pages Transmitted: _4)  Signature						
Typed or printed name Linda J. Remer		11		Date	May 08, 2006	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, proparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## **CENTRAL FAX CENTER**

## MAY - 8 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of: BARKER

Examiner:

JOHNSON, Jerrold D.

Patent No. 7,025,205

Art Unit:

3728

Issued: April 11, 2006

Application Serial No.: 10/603,214

TELEFAX CERTIFICATE

hereby certify that this correspondence is eing transmitted via facsimile to the omnissioner for Patents, Alexandria, VA

Filing Date: June 25, 2003

Title:

METHOD AND PACKAGING FOR

PRESSURIZED CONTAINERS

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Attn: Certificate of Correction Branch

Dear Sir:

## REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

It has been discovered that certain errors, as specified in the attached Certificate of Correction form (Form PTO-1050) occur in the above-identified U.S. Patent.

The errors found in the patent application are as follows:

Column 21, line 4: "wherein said barrier layer is. made of aluminum foil." should read as 1. -- wherein said barrier layer is made of aluminum foil.--.

Support for this correction can be found in the current specification at column 8, line 29; and also in Applicants' amendment filed November 22, 2005 at claim 82.

Column 22, line 33: "(i) pressurized MDI (metered dose inhaler) container " should read as 2. -- (i) a pressurized MDI (metered dose inhaler) container --.

Support for this correction can be found in current specification at column 8, line 35; and also in Applicants' amendment filed November 22, 2005 at claim 117.

Column 22, line 61: "30. A phannaceutical product according to claim 28, " should read as 3. -- 30. A pharmaceutical product according to claim 28, --.

Support for this correction can be found in the current specification at column 10, line 10; and also in Applicants' amendment filed November 22, 2005 at claim 119.

It is believed that these errors warrant the issuance of a Certificate of Correction and, in accordance with 37 C.F.R. §1.322, it is respectfully requested that a Certificate of Correction be issued and forwarded to the address below.

All of the above errors occurred during the printing of the patent and, therefore, no fee is due; however, the Commissioner is hereby authorized to charge any fees that are required by this paper to Deposit Account 18-1982.

Respectfully submitted

Dated

Paul R. Darkes, Reg. No. 33,862

Attorney for Applicant

sanofi-aventis
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800

Telephone (610) 889-8458

Telefax (908) 231-2626

sanofi-aventis Docket No. USAV2001/0077 US NP

Printer's Trim Line Stuple Here Only

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

> PATENT NO. : US 7,025,205 : April 11, 2006

: BARKER INVENTOR

DATED

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 21, line 4: "wherein said barrier layer is. made of aluminum foil." should read as -- wherein said barrier layer is made of aluminum foil. --.

Column 22, line 33: "(i) pressurized MDI (metered dose inhaler) container "should read as -- (i) a pressurized MDI (metered dose inhaler) container --.

Column 22, line 61: "30. A phannaccutical product according to claim 28, " should read as --30. A pharmaceutical product according to claim 28, --.

Mailing Address of Sender:

Patent No. 7,025,205

Paul R. Darkes, Reg. No., 33,862 U.S. Patent Operations sanofi-aventis Inc. LLC Route #202-206 P. O. Box 6800 Mail Code D-303A Bridgewater, New Jersey 08807-0800

Certificate of Correction (PTO Form 1050) - Amended